Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
- Thompson-Coon, Jo
- Hoyle, M
- Green, C
- Liu, Z
- Welch, K
- Moxham, T
- Stein, Ken
DOIAbstract
addresses: Peninsula Technology Assessment Group, Peninsula College of Medicine and Dentistry, University of Exeter, UK.types: Journal Article; ReviewPublished version. Copyright © 2010 NIHR Health Technology Assessment ProgrammeTo assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC)
Add to ORKG